Ribosomal protein L23a pseudogene 86 (RPL23AP86)

Ribosomal protein L23a pseudogene 86 (RPL23AP86) is classified as a *processed pseudogene* in the human genome, derived from the functional *ribosomal protein L23a (RPL23A)* gene[3][7]. Pseudogenes like RPL23AP86 are non-functional genomic elements and do not encode a functional protein product[2][7]. The functional gene, RPL23A, is a component of the ribosomal 60S subunit and participates in protein synthesis[1][3][5]. There are at least 90–100 or more known RPL23A pseudogenes in the genome (typically numbered, e.g. RPL23AP1–RPL23AP97, with some gaps)[3][7]. RPL23AP86 fits the pattern but lacks individually characterized function, druggability, or therapeutic significance[7]. Recent studies investigating other pseudogenes in this family (not specifically RPL23AP86) show that expression of related pseudogenes may be detectable in some tissues and have weak associations with cancer prognosis, but the functional role for any individual pseudogene, including RPL23AP86, is not supported by current evidence[7]. **Key points supporting 'is_incorrect: true':** - RPL23AP86 is a pseudogene, not a functional protein, enzyme, receptor, or other classically druggable target[2][3][7]. - There is no evidence it is a validated therapeutic target or that it has a direct biological function[2][7]. - The number "86" fits the systematic pseudogene nomenclature (e.g., RPL23AP53, RPL23AP97), but almost all members of this family lack individual experimental characterization[3][7]. **Aliases:** Standard nomenclature is simply "RPL23AP86," following the processed pseudogene numbering for ribosomal proteins[3]. **Molecular classification:** Pseudogenes are typically classified outside classical molecular families; here "Other (pseudogene)" applies. **Biological functions:** Pseudogenes like RPL23AP86 are generally considered non-functional relics and are not implicated in canonical cellular processes, though rare exceptions exist for some pseudogenes in the genome. **Disease roles:** No direct evidence for disease association or therapeutic relevance for RPL23AP86. Any apparent role in disease relates to expression of the functional RPL23A gene or, in rare pseudogene cases, dysregulation in cancer (primarily shown for RPL23AP53 or the main RPL23A, not RPL23AP86)[7]. **Interacting drugs, mechanisms of action, biomarkers, safety concerns:** None known. There are no drugs or mechanisms described for targeting RPL23AP86, nor is it used as a biomarker or associated with specific safety or therapeutic challenges[5][7]. **Summary/description:** Ribosomal protein L23a pseudogene 86 (RPL23AP86) is a processed pseudogene derived from the RPL23A gene, which encodes a component of the 60S ribosomal subunit. RPL23AP86 does not produce a functional protein, is not a therapeutic target, and does not contribute directly to cellular processes or disease biology as currently understood. Its main relevance is as a marker within genomic studies cataloguing ribosomal pseudogenes[2][3][7].

Other names

Ribosomal protein L23a pseudogene 86RPL23AP86